Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Black soybean extract cream (BSEC) is a topical therapeutic agent being evaluated for its efficacy in preventing and managing radiation-induced dermatitis (RID) and associated pain in patients with head and neck cancer. The cream utilizes the antioxidant and anti-inflammatory properties of black soybean (*Glycine max* L. Merr) extracts, which are rich in bioactive compounds such as anthocyanins and isoflavones. Clinical data from Phase I trials suggest that BSEC can significantly reduce the severity of skin reactions and improve the quality of life for patients undergoing radiotherapy by maintaining low pain scores and minimizing skin breakdown.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on black soybean extract cream.